Open AccessSTUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE
Author(s) -
А. Н. Стуков,
S.F. Vershinina,
Н. А. Козявин,
Т. Ю. Семиглазова,
Лариса Филатова,
D.Kh. Latipova Latipova,
A.O. Ivantsov,
В. Г. Беспалов,
Александр Леонидович Семёнов,
О. А. Беляева,
Galina S. Kireeva,
В. А. Александров,
G.V. Tochilnikov,
И. Н. Васильева,
М. А. Майдин,
Margarita L. Tyndyk,
Stepan Kruglov,
Г. А. Янус,
М. Н. Юрова
Publication year - 2019
Publication title -
sibirskij onkologičeskij žurnal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.115
H-Index - 4
eISSN - 2312-3168
pISSN - 1814-4861
DOI - 10.21294/1814-4861-2019-18-5-54-60
Subject(s) - lomustine , medicine , breast cancer , carmustine , cancer , tumor progression , chemotherapy , pathology , oncology , cyclophosphamide , vincristine
Because of the high risk of brain metastases from HER2-positive breast cancer, the study of the anticancer activity of drugs used to treat brain tumors, in particular lomustine, is of great importance. In the FVB/N Her-2 transgenic mice bearing HER2-positive breast cancer (BC HER2+), a single oral administration of lomustine at a dose of 50 mg/kg resulted in a significant tumor growth inhibition (up to 96 %, p<0.0001). The tumor growth index (TGI) expressed as a ratio between the areas under the kinetic curves of tumor growth in the study and control groups and amounted to 33 % (p<0.001) indicated the high activity of lomustine. However, the effect of lomustine on intramuscularly transplanted Ehrlich tumor was insignificant (tumor growth inhibition and tumor growth index were <39 % and 68 %, respectively). Lomustine administered orally at a single dose of 50 mg/kg 24 hours after intracranial transplantation of BC HER2+ increased the median survival time up to 30 days in FVB/N mice compared to 21 days in the control group mice (p<0.001). The high therapeutic effect of lomustine in HER2-positive breast cancer mice is likely can be explained by the biological characteristics of this tumor; therefore clinical trials of lomustine for HER2-positive tumors are needed.